SNAP trial seeks to improve treatments for Staph aureus bloodstream infections

Every year, about 5000 patients in Australia develop a bloodstream infection due to Staphylococcus aureus (golden staph). Approximately 20 per cent will die within 30 days and each person requires a minimum of two weeks of intravenous antibiotics. Few clinical trials have been conducted to advance treatments.

The Staphylococcus aureus Network Adaptive Platform trial (SNAP) aims to improve treatments for Staph aureus bloodstream infections. SNAP will involve more than 60 hospitals around the world and aims to recruit 6000 patients with Staph aureus bloodstream infections. The trial is sponsored by the University of Melbourne, led by Associate Professor Steven Tong from the Doherty Institute and the Department of Infectious Diseases, and funded by the NHMRC and national agencies in Canada and NZ.

Recruitment to the trial will commence in the second half of 2021. As the largest trial for Staph aureus bloodstream infections (the largest so far included 750 patients), SNAP will address multiple questions in parallel including what are the best initial antibiotics to use, whether adjunctive therapy is beneficial, and whether intravenous antibiotic therapy can be safely switched to oral therapy.

SNAP is being designed as a pragmatic trial that facilitates broad involvement and intends to include many University of Melbourne affiliated hospitals as trial sites including a range of principal referral hospitals as well as regional hospitals. In addition, specific patient populations that are often excluded from such trials will be eligible for the study. These include children, pregnant women, and people who inject drugs.

For more information, visit www.snaptrial.com.au